Imatinib therapy for hypereosinophilic syndrome and eosinophilia- associated myeloproliferative disorders

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


A pathogenetic mutation, FIP1L1-PDGFRA, that results from an interstitial chromosome 4q12 deletion, leads to a constitutive activation of the platelet-derived growth factor receptor-α (PDGFRA) tyrosine kinase as well as a disease phenotype that mimics both the hypereosinophilic syndrome (HES) and systemic mast cell disease associated with eosinophilia (SMCD-eos). Complete remissions, in response to treatment with low-dose imatinib mesylate (100mg/day or less) have now been documented in all cases of FIP1L1-PDGFRA + eosinophilic disorder as well as other eosinophilic disorders that carry activation mutations of the PDGFRB gene that is located on chromosome 5q33. Furthermore, response to therapy has been rapid (within days) and durable. Interestingly, imatinib mesylate treatment, at a higher dose level (400mg/day), might induce either partial or short-lived complete remissions in HES that is not associated with the aforementioned PDGFR mutations. These observations make it necessary to re-examine current disease classification and treatment algorithms in eosinophilic disorders.

Original languageEnglish (US)
Pages (from-to)47-52
Number of pages6
JournalLeukemia Research
Issue numberSUPPL. 1
StatePublished - May 2004


  • Eosinophilia
  • Hypereosinophilic syndrome
  • Imatinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Imatinib therapy for hypereosinophilic syndrome and eosinophilia- associated myeloproliferative disorders'. Together they form a unique fingerprint.

Cite this